Commissioning and clinical results utilizing the Gildenberg-Laitinen Adapter Device for X-ray in fractionated stereotactic radiotherapy

Reproducibility and geometric accuracy of the Fixster system during hypofractionated stereotactic radiotherapy

Background

Hypofractionated radiotherapy has been used for the treatment of AVMs and brain metastases. Hypofractionation necessitates the use of a relocatable stereotactic frame that has to be applied on several occasions. The stereotactic frame needs to have a high degree of reproducibility, and patient positioning is crucial to achieve a high accuracy of the treatment.

Methods

In this study we have, by radiological means, evaluated the reproducibility of the isocenter in consecutive treatment sessions using the Fixster frame. Deviations in the X, Y and Z-axis were measured in 10 patients treated with hypofractionated radiotherapy.

Results

The mean deviation in the X-axis was 0.4 mm (range -2.1 – 2.1, median 0.7 mm) and in the Y-axis -0.3 mm (range -1.4 – 0.7, median -0.2 mm). The mean deviation in the Z-axis was -0.6 (range -1.4 – 1.4, median 0.0 mm).

Conclusion

There is a high degree of reproducibility of the isocenter during successive treatment sessions with HCSRT using the Fixster frame for stereotactic targeting. The high reducibility enables a safe treatment using hypofractionated stereotactic radiotherapy.

Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results

Management of Malignant Gliomas continues to be a challenge. We prospectively studied the role of adding weekly Paclitaxel to Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of Malignant Gliomas. Twenty-three Glioblastoma Multiforme and two Anaplastic Astrocytoma were studied. Patients received 46 Gy at 2 Gy/fraction followed by a boost utilizing FSRT at a fraction of 2.5 Gy for 8 fractions. Paclitaxel is delivered concomitantly at 150 mg/m(2) weekly for six cycles. Eighteen patients had pharmacokinetic assays of Paclitaxel levels. All patients were followed until death or for a maximum of 36 months. The overall survival of the whole group was 14 months. The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months. Higher survival (14 months) was noted in the subtherapeutic phenytoin level group compared to 10 months in the therapeutic group (P=0.271). No grade 4 CTCAE (version 3.0) toxicities were observed. Enhanced survival was demonstrated with gross tumor resection (20.8 months), KPS > or =80 (18.7 months) and age < or =60 years (27 months) as compared to subtotal resection or biopsy (12.1 months, P< 0.005), KPS < or =70 (10.8 months, P=0. 005) and older age > 60 (10.46 months, P=0.006), respectively. Our study suggests that: i) the use of weekly Paclitaxel and FSRT in Gliomas is well tolerated with a survival of 14 months; ii) the regimen resulted in improvement of survival of RPA classes IV, V, VI; and iii) the use of FSRT boost may be studied with other chemotherapeutic agents to see if superior results can be attained.

A simple device for high-precision head image registration: Preliminary performance and accuracy tests

The purpose of this paper is to present a new device for multimodal head study registration and to examine its performance in preliminary tests. The device consists of a system of eight markers fixed to mobile carbon pipes and bars which can be easily mounted on the patient's head using the ear canals and the nasal bridge. Four graduated scales fixed to the rigid support allow examiners to find the same device position on the patient's head during different acquisitions. The markers can be filled with appropriate substances for visualisation in computed tomography (CT), magnetic resonance, single photon emission computer tomography (SPECT) and positron emission tomography images. The device's rigidity and its position reproducibility were measured in 15 repeated CT acquisitions of the Alderson Rando anthropomorphic phantom and in two SPECT studies of a patient. The proposed system displays good rigidity and reproducibility characteristics. A relocation accuracy of less than 1,5 mm was found in more than 90% of the results. The registration parameters obtained using such a device were compared to those obtained using fiducial markers fixed on phantom and patient heads, resulting in differences of less than 1 degree and 1 mm for rotation and translation parameters, respectively. Residual differences between fiducial marker coordinates in reference and in registered studies were less than 1 mm in more than 90% of the results, proving that the device performed as accurately as noninvasive stereotactic devices. Finally, an example of multimodal employment of the proposed device is reported.

New Radiation Therapy Techniques for the Treatment of Head and Neck Cancer

This article reviews the most recent technology used in the treatment of head and neck cancer. It discusses brachytherapy, new ways to mix radionuclides for enhanced radiobiologic effects, and different fractionation schemes that have grown in clinical importance. Intensity-modulated radiotherapy has become a mainstay in head and neck cancer treatment, and the authors discuss several popular and emerging approaches. Patient immobilization and imaging are also discussed.

Modification of Gill-Thomas-Cosman frame for extracranial head-and-neck stereotactic radiotherapy

PURPOSE

A modification of a commercially available, noninvasive, relocatable, stereotactic Gill-Thomas-Cosman (GTC) head frame is presented for treatment of extracranial lesions of the head and neck, base of the skull, and inferior nasopharyngeal region.

METHODS AND MATERIALS

Skull-based and nasopharyngeal lesions cannot be treated with the GTC frame because it obstructs the beam path. To treat those lesions, the GTC frame was modified without compromising the integrity, flexibility, or use of the treatment software. The modification uses a set of aluminum extension rods of variable lengths and bevels to support a modified dental plate. The extension rods allow the dental tray and attached GTC frame to be lowered so that the more inferior regions may be treated. Ten patients underwent CT with the modified frame and CT localizer. For some patients, MRI was acquired without the frame. Image fusion of MRI and CT scans was used to delineate the target volume, and planning was done with the existing software for proper treatment.

RESULTS

The modification of the GTC frame has been successful in imaging, planning, and extending the treatment domain for the base of the skull, nasopharyngeal regions, and other superior lesions of the head and neck. The reproducibility of the modified frame and the patient localization helmet technique was identical to that of the unmodified frame.

CONCLUSION

The modification of the GTC frame is simple and accurate. It provides flexibility in treating an extended range of the base of the skull, nasopharyngeal region, and other superior lesions of the head and neck that otherwise could not be treated with the GTC frame.